| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2005PNAS..10212903B |
| P356 | DOI | 10.1073/PNAS.0502449102 |
| P932 | PMC publication ID | 1200264 |
| P698 | PubMed publication ID | 16129831 |
| P5875 | ResearchGate publication ID | 7630772 |
| P2093 | author name string | Michael D Miller | |
| Renee Hrin | |||
| Elisabetta Bianchi | |||
| Romas Geleziunas | |||
| William A Schleif | |||
| Antonello Pessi | |||
| Marco Finotto | |||
| Paolo Ingallinella | |||
| Xiaoli S Hou | |||
| Anthony V Carella | |||
| P2860 | cites work | Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 |
| Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41 | Q24533287 | ||
| Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket | Q27619965 | ||
| Core structure of gp41 from the HIV envelope glycoprotein | Q27736064 | ||
| Atomic structure of the ectodomain from HIV-1 gp41 | Q27738021 | ||
| Atomic structure of a thermostable subdomain of HIV-1 gp41 | Q27746904 | ||
| Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues | Q27766102 | ||
| The structural biology of type I viral membrane fusion | Q28188215 | ||
| A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition | Q28317348 | ||
| Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor | Q28346124 | ||
| Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region | Q28360391 | ||
| A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody | Q28369126 | ||
| Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target | Q28369397 | ||
| A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication | Q28646734 | ||
| Mechanisms of viral membrane fusion and its inhibition | Q29616090 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Protein design of an HIV-1 entry inhibitor | Q32067748 | ||
| Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics | Q34415921 | ||
| Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes | Q35697595 | ||
| High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques | Q35794138 | ||
| Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex | Q35997611 | ||
| Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. | Q38356421 | ||
| Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 | Q39612212 | ||
| Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion | Q39682931 | ||
| De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies | Q40570803 | ||
| Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity | Q40797427 | ||
| The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure | Q42564829 | ||
| Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up | Q42680685 | ||
| Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design | Q44141083 | ||
| Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives | Q44774354 | ||
| HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications | Q44907220 | ||
| HIV vaccine design and the neutralizing antibody problem | Q46474020 | ||
| Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. | Q52545389 | ||
| The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation | Q73325759 | ||
| Enfuvirtide | Q73411068 | ||
| An isoleucine zipper peptide forms a native-like triple stranded coiled coil in solution | Q77757706 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 12903-12908 | |
| P577 | publication date | 2005-08-29 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection | |
| P478 | volume | 102 |
| Q33966639 | A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41 |
| Q42717107 | A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment |
| Q39411795 | A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency. |
| Q37153758 | Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency |
| Q33523258 | Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 |
| Q55237287 | An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. |
| Q30843874 | Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. |
| Q35692292 | Artificial 64-Residue HIV-1 Enhancer-Binding Peptide Is a Potent Inhibitor of Viral Replication in HIV-1-Infected Cells |
| Q28471980 | Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding |
| Q34020570 | Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations |
| Q35563298 | Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design |
| Q83961343 | Biophysical characterization of HRC peptide analogs interaction with heptad repeat regions of the SARS-coronavirus Spike fusion protein core |
| Q37065151 | Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions |
| Q37777033 | Coiled coils: attractive protein folding motifs for the fabrication of self-assembled, responsive and bioactive materials |
| Q24632790 | Complex networks govern coiled-coil oligomerization--predicting and profiling by means of a machine learning approach |
| Q27303525 | Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41 |
| Q39943795 | Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition |
| Q34298481 | Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket |
| Q27650133 | Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency |
| Q37789224 | Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41 |
| Q24681004 | Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205 |
| Q99625242 | Entry Inhibitors: Efficient Means to Block Viral Infection |
| Q38076139 | Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors |
| Q33249271 | Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation |
| Q43488425 | Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies. |
| Q36749473 | HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications |
| Q47893467 | In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin |
| Q37831811 | Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. |
| Q34259602 | Investigation of the network of preferred interactions in an artificial coiled-coil association using the peptide array technique. |
| Q43627216 | Kinetic dependence to HIV-1 entry inhibition |
| Q34059855 | Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design |
| Q35729956 | Membrane-Active Sequences within gp41 Membrane Proximal External Region (MPER) Modulate MPER-Containing Peptidyl Fusion Inhibitor Activity and the Biosynthesis of HIV-1 Structural Proteins |
| Q28475682 | Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action |
| Q27665557 | Molecular basis of coiled-coil oligomerization-state specificity |
| Q34055847 | Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides |
| Q37562113 | Peptides in the treatment of AIDS. |
| Q36310717 | Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors |
| Q36095908 | Potent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20 |
| Q36458359 | Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1. |
| Q34793125 | Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs. |
| Q38741307 | Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity |
| Q37209050 | Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. |
| Q34412591 | Small Molecule Mimetics of an HIV-1 gp41 Fusion Intermediate as Vaccine Leads |
| Q27678208 | Structural Basis for the Oligomerization-State Switch from a Dimer to a Trimer of an Engineered Cortexillin-1 Coiled-Coil Variant |
| Q54040210 | Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. |
| Q79283922 | Surface simulation synthesis: a new strategy to spy alpha-helix structure |
| Q26770255 | Synthetic Peptides as Protein Mimics |
| Q34412839 | The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry |
| Q93062907 | Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry |
| Q33935016 | Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates |
| Q27689547 | Versatile C(3)-symmetric scaffolds and their use for covalent stabilization of the foldon trimer |
| Q34281656 | Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. |
Search more.